Weight-Loss drug wegovy could boost heart ablation success
NCT ID NCT07275697
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether taking semaglutide (Wegovy) for at least three months before a first-time atrial fibrillation ablation can improve heart rhythm outcomes. 200 overweight or obese adults scheduled for ablation will be randomly assigned to either standard care or semaglutide plus lifestyle advice. The main goal is to see if semaglutide reduces the chance of abnormal heart rhythms returning within a year after the procedure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Semaglutide (Wegovy), a weight-loss drug
What this could lead to
If successful, this could show that using a weight-loss drug before heart ablation improves long-term heart rhythm control and reduces the need for repeat procedures.
What could go wrong
This is a Phase 4 trial with only 200 participants, so results may not apply to everyone. Semaglutide can cause side effects like nausea, vomiting, and diarrhea.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION (AF) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Karolinska University Hospital
Stockholm, 141 86, Sweden
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••